Robert Fowler to Treatment Outcome
This is a "connection" page, showing publications Robert Fowler has written about Treatment Outcome.
Connection Strength
0.079
-
Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials. 2021 Mar 22; 22(1):224.
Score: 0.008
-
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 05; 9(5):522-532.
Score: 0.008
-
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 10 06; 324(13):1317-1329.
Score: 0.008
-
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clin Trials. 2020 10; 17(5):491-500.
Score: 0.008
-
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020 Jan 03; 21(1):8.
Score: 0.008
-
Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza Other Respir Viruses. 2019 07; 13(4):382-390.
Score: 0.007
-
Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) Study: Reverse Transcription-Polymerase Chain Reaction and Cataract Surgery Outcomes of Ebola Survivors in Sierra Leone. EBioMedicine. 2018 Apr; 30:217-224.
Score: 0.007
-
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 03 15; 197(6):757-767.
Score: 0.007
-
7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. Trials. 2018 Feb 17; 19(1):111.
Score: 0.007
-
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30; 19(1):81.
Score: 0.007
-
Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: a decision analysis. Mov Disord. 2010 Jul 30; 25(10):1456-63.
Score: 0.004